BAY 987519
Phase 3Small molecule
BayerBAY 987519 is one of 280 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 3.
8
Indications
28
Total Trials
4
Active Trials
279
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1BAY 987519
BayerPhase 3
Mekinist
NovartisPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Prednisone/prednisolone
RochePreclinical
Triptorelin Pamoate
IpsenPreclinical
Therapeutic Hydrocortisone
EEastern Cooperative Oncology Group
Preclinical
Ifex
BBaxter Healthcare Corporation
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
TIA2 trials
Type 2 Diabetes Mellitus1 trial
14 more indications
Effectiveness1 trial
Hemophilia1 trial
Solid Tumors1 trial
Drug1 trial
Congestive Heart Failure1 trial
Prostate Cancer1 trial
Absorption1 trial
Hepatocellular Carcinoma1 trial
Alport syndrome1 trial
MTAP-deleted Solid Tumors1 trial
Unspecified9 trials
Show 6 more trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BAY 987519. EMBL-EBI & Wellcome Sanger Institute.
- [4]